Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Off-target DNA insertions are unintended sequence changes that occur away from the genomic site an editor was designed to modify. They are a potential safety concern because an insertion, deletion, rearrangement or translocation could alter gene function or genome integrity. However, no single percentage describes the risk for every CRISPR system, guide RNA, cell type, delivery method or patient. Risk has to be measured for the specific product and the cells it is intended to treat.
What “off-target DNA insertion” actually means
Two terms are being combined in this phrase. Off-target describes location: the change happened somewhere other than the intended genomic target. Insertion describes one type of sequence change: extra DNA has been added at that location. An off-target event might instead be a small deletion, a substitution, a larger rearrangement or a chromosome-level translocation.
As an Amazon Associate I earn from qualifying purchases.
CRISPR literature also uses “DNA bulge” for a mismatch configuration in which the guide RNA and genomic DNA are not the same length. A bulge is a feature of recognition between the guide and DNA; it is not the same thing as a DNA fragment being inserted into a chromosome. Analyses that search only for ordinary base mismatches can therefore miss potential sites with bulges.
The main categories scientists separate
| Event | What happens | Why it matters |
|---|---|---|
| Small insertion or deletion (indel) | Repair after a cut adds or removes a few bases, often near a cleavage site. | It can disrupt a coding sequence or regulatory element, although many indels have no measurable functional effect. |
| Off-target cleavage and repair | The editor cuts a similar but unintended genomic sequence and the cell repairs it inaccurately. | The resulting mutation may affect a gene or control region. |
| Large structural variant | A deletion, duplication, inversion or other change spans hundreds or thousands of bases. | Small-variant assays may miss it, and several genes or regulatory regions can be affected at once. |
| Chromosomal translocation | Broken DNA ends from different chromosomes join together. | It can create abnormal gene fusions or destabilize the genome. |
| Donor or vector integration | Intended donor DNA or delivery-vector DNA integrates at an unintended location. | The inserted sequence, its regulatory elements and the integration site may have biological effects. |
Regulators treat off-target edits and translocations as possible risks and expect chromosomal integrity to be evaluated. The available evidence does not establish a general incidence for unintended donor- or vector-DNA integration, so that possibility should not be presented as a universal event rate.
#1 Best Overall
- [Ultra-Lightweight Ear Buds Designed for Small Ears] Each earbud weighs only 3.7g and features a compact, ergonomic in-ear design made especially for small ears. Secure, low-profile, and comfortable for workouts, all-day wear or overnight sleeping.The ultra-slim profile sits flush in your ear with no hard edges poking or rubbing, so you can even sleep on your side without discomfort.
- [Immersive Stereo Sound with TOZO OrigX Technology] TOZO OrigX tuning delivers clear vocals, balanced mids, and natural stereo sound for music, podcasts, and videos.
- [Long Battery Life for Daily Use] Get up to 7 hours of playtime on a single charge, with up to 32 hours total using the charging case—ideal for workdays, commuting, and extended listening sessions.
- [Bluetooth 5.3 & Stable Connection] Bluetooth 5.3 provides fast pairing, stable wireless performance, and reduced dropouts as you move around home or office.
- [Deep Bass with Clear Vocals] High-performance drivers produce punchy bass while keeping vocals clean and detailed for everyday listening.
Why an off-target change could be harmful
An off-target edit is not automatically dangerous. Its consequence depends on the affected genomic region, the exact sequence change, the cell in which it occurs and what happens to that cell afterward. A change in a nonfunctional stretch of DNA may have little observable effect. The same-sized change inside a tumor-suppressor gene, a growth-control gene or an important regulatory element could be consequential.
Possible biological consequences
- Loss of gene function: an insertion or deletion can interrupt the coding sequence or alter how a gene is spliced.
- Abnormal gene regulation: a structural change can move a promoter or enhancer next to a different gene.
- Genome instability: multiple breaks or faulty repairs can produce translocations, inversions or other rearrangements.
- Clonal expansion: if an edited cell gains a survival or growth advantage, it may become more common than other treated cells.
- Loss of normal cell performance: a change in a specialized cell could impair the function the therapy is meant to restore.
These are potential outcomes, not predictions that every off-target event will cause cancer, treatment failure or another clinical injury. A safety assessment must connect a detected variant to its location, biological effect and persistence in the treated cell population.
Somatic treatment is different from germline editing
Most clinical gene-therapy discussions covered by United States regulatory guidance concern somatic cells: cells treated in one person, with changes not intended to be passed to future children. Editing an embryo, egg, sperm or early reproductive cell raises separate questions because a change could be inherited. The National Human Genome Research Institute describes distinct safety and ethical concerns for reproductive editing. Those concerns should not be folded into a risk estimate for a somatic treatment.
What studies have found—and what their numbers do not mean
Published results demonstrate that off-target activity and large unintended changes can be detected under some conditions. They do not provide a universal clinical incidence.
Rank #2
- 【IP68 Waterproof Multifunctinal Smart Watch】Torjalph fitness activity tracker smart watch is IP68 waterproof technology ,you can wear it when swimming,handwashing,it's rain-proof which means that you perform multiple exercise modes outside without worrying about sweat or rain corroding your fitness smart watch,and this watch equipped with a 230 mAh large capacity battery magnetic charging ,and this sports activity tracker watch can be used 5-7 days If fully charged.
- 【Larger 1.83'' Full Screen Watch & Multi-dial Selection】1.83 inch full HD color touch screen smart watch for men / women provides excellent 240*284 resolution image quality ,This Bluetooth smart watch offers a better touch experience and remarkable immersion and ,more than 200 watch faces for you to choose from App"Da Fit ", you can change the dial style according to your mood to wear keeping the world on your wrist
- 【Accurate Activity Tracker Smart Watch 】sports watch activity tracker uses sweat and dust resistant breathable silicone strap, our Fitness Tracker Smart Watch for Android iOS Phones supports 12 sports modes,walking,running,bicycle,swimming,badminton,basketball,football,rope skipping. This bluetooth calls smart watch for men women is lightweight and stylish, bringing more convenient and relaxing sports experience while also providing more protection.
- 【Your 24 Hour Personal Daily Health Monitor】Fitness watch for women men full touch screen IP67 waterproof bluetooth smartwatch for Android iOS Phones with heart rate blood pressure monitor multifunction Andriod smart watch with steps counter sleep monitor sports fitness watch, monitoring blood oxygen saturation allows you to understand your physical condition in real time to track fitness progress ,to know your health status in time.
- 【More Functions Bluetooth Call Smart Watch】This fitness activity smart watch full screen for iPhone and Android phones includes a bunch of new features including:The bluetooth smart watch can hang up the phone, receive and display WhatsAPP /Text /Facebook /Twitter /Messenger reminder.Support sedentary reminder, alarm clock, stopwatch, timer,weather information,music control, remote camera control compatible with Android 5.0 and above or iOS 9.0 and above smartphones.
| Study or program | Finding | How to interpret it |
|---|---|---|
| U.S. Food and Drug Administration regulatory-science project, completed 2023 | Nine off-target sites were found among more than 2,000 sites assayed in a study using clinically relevant transient Cas9 delivery in primary human cells and established guide RNAs. A high-fidelity Cas9 reduced off-target activity compared with wild-type Cas9 in the tested conditions. | This is a result for those editors, guides, cells and delivery conditions—not a rate for all products, patients or treatments. |
| CRISPR/Cas9 bulge study, indexed in PubMed, 2014 | Fifteen confirmed off-target sites were identified among 114 putative loci. The sites contained a single-base bulge and one to three mismatches to the guide strand. | The finding supports searching for DNA and RNA bulges as well as ordinary mismatches. It is not a clinical event rate. |
| Structural-variant study, indexed in PubMed, 2023 | Whole-genome analysis identified deletions of 91.2 kilobases and 136 kilobases at atypical, nonhomologous off-target sites in two edited cell lines. | Large changes can be missed by assays limited to small local edits. Two cell lines cannot establish how often such deletions occur in people. |
| Nature Communications zebrafish study, 2022 | Structural variants of at least 50 base pairs represented 6% of editing outcomes in founder larvae. The guides had been selected for in-vitro off-target activity, and outcomes were followed across generations. | This is an embryo and animal-model observation under deliberately sensitive conditions, not a human treatment risk. |
The FDA project’s comparison of wild-type and high-fidelity Cas9 illustrates why editor choice matters, but it does not make a high-fidelity nuclease universally safe. Performance still depends on guide sequence, exposure, delivery and the relevant cell type.
Can CRISPR edit the wrong part of DNA?
Yes. Cas9 and other editors use a guide sequence to recognize a target, but recognition can tolerate some mismatches. Sites with similar sequences, unusual DNA structures or bulges may be cut or edited. The cell’s repair pathways then determine whether the result is a small indel, a larger rearrangement or another outcome.
Factors that change the risk profile
- Editing modality: a nuclease that makes a double-strand break has different failure modes from a base editor or prime editor.
- Guide sequence: some guides have many plausible near-matches; others have fewer. Prediction tools trade sensitivity against specificity.
- Editor fidelity and exposure: engineered high-fidelity nucleases and transient delivery can reduce activity at some unintended sites, while prolonged exposure may provide more opportunity for mis-editing.
- Cell source and state: primary cells, stem cells and immortalized cell lines can differ in DNA repair, growth and clonal behavior.
- Delivery conditions: dose, route, duration and whether DNA, RNA or a protein complex is delivered affect the number and duration of cells exposed.
- Repair environment: the same cut can produce different products in different cells or at different stages of growth.
Because these variables interact, a result obtained with one guide or cell line cannot simply be transferred to another therapy.
How scientists test for off-target edits
A credible assessment combines prediction, targeted measurement and broader genome-integrity testing. No single assay can prove that every possible unintended change has been excluded.
Rank #3
- [Low Noise High Fidelity] New bee guitar cord with 22AWG oxygen-free-copper center conductors provides enhanced signal transfer, the PVC insulation material and the high-density stranded copper double shield provide noise rejection for quiet operation
- [Ideal for Choice] New bee 1/4 straight and right angle metal connectors, ensures a secure connection in any instrument, pedal, or amp jack. L shape great fro on stage guitar stands
- [Wide Compatible] Suitable for mixer, power amplifier, microphone, effector, decoder, equalizer, electoronic organ, electric guitar, electric bass and other electronic equipments. Widely used in the installation of smart home, karaoke speaker, professional stage audio, etc
- [Easy Disassemble] Making incidental repairs quick and easy! Very nice, flexible cable
- [Dont Hesite to Order] 24 hours customer services and professional technology team are standing by
- Define the product and intended edit. Investigators document the editor, guide, donor template if used, delivery format, dose, exposure time and the relevant manufacturing or treatment material.
- Predict candidate sites. Computational methods search for sequences resembling the guide, including mismatch and bulge configurations. These methods help prioritize testing; a predicted site is not evidence that editing occurred.
- Sequence high-priority sites deeply. Targeted next-generation sequencing can measure low-frequency variants at nominated loci. Assay design must account for amplification artifacts, read errors and the detection limit.
- Use genome-wide methods when justified. Genome-wide sequencing or other unbiased approaches can reveal changes outside a predefined candidate list. Their value depends on coverage, read quality, bioinformatics and the type of variant being sought.
- Look for structural and chromosomal changes. Long deletions, inversions, copy-number changes and translocations require methods capable of detecting them; a small-amplicon assay alone is insufficient.
- Test relevant samples. Samples should represent the actual edited cell product or treated tissue, with appropriate controls and enough independent material to detect low-frequency events.
- Investigate biological significance. Variants that are detected should be mapped to genes and regulatory regions, evaluated for persistence or clonal expansion and, where appropriate, followed with functional assays.
The FDA’s sequencing recommendations address off-target assessment, on-target analysis, chromosomal integrity, sample selection, sequencing, bioinformatics and reporting. They emphasize that feasible candidate-site lists and analytical methods depend on the particular editing conditions.
Why prediction and sequencing each have limits
A prediction algorithm can miss an unusual site or overpredict a site that is never edited. Sequencing a finite list of loci cannot show that all other loci are clean. Conversely, a genome-wide assay may have insufficient sensitivity for rare variants or may not reliably detect every large rearrangement. The relevant question is not whether one test was negative, but whether the combined strategy could detect the classes of change that matter for that product.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Does a negative test mean there is no risk?
No. A negative result means that no change was detected above that assay’s validated detection limit in the samples tested. It does not establish that the event is impossible, absent from every treated cell or incapable of appearing later through clonal expansion.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallConfidence in a negative finding is stronger when the study uses the intended clinical material, sufficient sequencing depth, validated error controls, independent samples and tests that cover both small variants and structural or chromosomal abnormalities. Reporting should state the detection limit and the regions or variant classes that were not assessed.
Rank #4
- Digital Family Calendar: BSIMB digital calendar wall touch screen puts an end to your chaotic life. Designed for busy families, the digital calendar keeps you organised and in step with your family. Assign different colours and tasks to each family member to make family scheduling easier and more intuitive.
- Easy Setup and Auto-Sync: Plug in, connect to WLAN and auto-syn your electric calendar in minutes. Digital wall calendar compatible with Google calendar, iCloud calendar, Outlook calendar, Cozi calendar and Yahoo calendar. Add events directly on the device or through the ecalendar app. Electronic calendar stays current whether you're at work or traveling—no manual updates needed.
- All-In-One Home Assistant: Smart calendar builds habits and encourage independence with personalised chores. Display daily meal plan to reduce the daily ‘What's for dinner?’ stress. To-do lists keep track of everything you want. Turning chores into valuable achievements with stars and rewards, making life easier and more enjoyable.
- Manage Anytime Anywhere: BSIMB electronic calendar for family stay connected with the powerful ecalendar app. Access and manage your digital wall calendar anytime, anywhere with free features like stars & rewards, photo screensaver, chore charts, meals plans, to-do lists etc. Electronic planner paid features like Magic Import tailor advanced tools for users with special needs.
- Stay in Touch with Loved Ones: Share photos or videos from your phone to electronic wall calendar with app, instantly update your life moment, and keep in touch with your family, especially those who are far away; you can also surprise your smart calendar digital wall by sending him a wish card; it's also great for keeping tech-illiterate elders in touch with the youngsters.
How to interpret an off-target percentage
Percentages are meaningful only with their denominator and conditions attached. “Nine sites among more than 2,000 assayed” refers to sites detected in one FDA project, not nine percent of patients or nine percent of all possible sites. “Six percent of outcomes” in zebrafish refers to founder larvae under that study’s guide-selection and model conditions, not six percent of human treatments.
When comparing studies, check:
- the editor and guide sequence;
- the cell type, species and developmental stage;
- the delivery format, dose and exposure duration;
- whether the assay was targeted or genome-wide;
- the smallest variant it could detect and whether it captured large structural changes;
- the number and origin of samples; and
- whether the result came from a model system or the intended therapeutic material.
What United States FDA guidance says
The FDA’s January 2024 guidance is final. It covers product design, manufacturing and testing, nonclinical safety assessment and clinical-trial design for human gene-therapy products that incorporate genome editing.
On April 14, 2026, the FDA issued Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing as a draft guidance labeled “Draft – Not for Implementation.” It describes nonbinding recommendations unless a specific legal requirement applies; it is not a finalized rule. Its publication status should be checked before relying on it for a filing.
“Therefore, an adequate assessment to evaluate off-target editing risk and impact on chromosomal integrity of human GE products is crucial to minimize unintended changes in the target cells or tissues.”
— U.S. Food and Drug Administration, Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry, April 2026
Questions to ask about a specific genome-editing treatment
Patients and research participants cannot infer a treatment’s risk from a headline percentage in another study. Useful questions for the treating team or sponsor include:
- Which editor, guide and delivery system are being used?
- Were the tests performed on the actual manufactured cell product or treated tissue?
- Which mismatch and bulge sites were evaluated, and how were they selected?
- What was the validated detection limit for rare edits?
- Did testing cover large deletions, inversions, copy-number changes and translocations as well as small indels?
- How will edited cells be monitored for persistence or clonal expansion?
- Which results are established for this product, and which are extrapolated from cell lines or animals?
These questions turn the broad phrase “off-target risk” into a product-specific assessment of what was tested, what was detected and what remains uncertain.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
